AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04574869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo control will be commercial sterile saline (0.9% Sodium Chloride Injection, United States Pharmacopoeia \[USP\]).
Study NCT04574869 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo control will be commercial sterile saline (0.9% Sodium Chloride Injection, United States Pharmacopoeia \[USP\]).
Study NCT04574869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071 10 mg/kg
Description: Multiple dose IV infusion of 10 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
Study NCT04574869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071 40 mg/kg
Description: Multiple dose IV infusion of 40 mg/kg RLS-0071 administered every 8 hours for approximately 3 days (9 consecutive doses)
Study NCT04505956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser lithotripsy without Moses Technology
Description: Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned off.
Study NCT06633484 — intervention group
Intervention type: OTHER
Intervention: functional magnetic resonance imaging
Description: non-diagnostic, non-invasive, passive measurement of the brain\&#39;s structure and function
Study NCT06634108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: The genistein capsules are manufactured and obtained from MCS Formulas, and each capsule contains 250 mg genistein and 50 mg inulin. The genistein is certified to be 98% pure genistein by HPLC and is certified by Good Laboratory Practice (GLP). They will consume 250 mg of genistein BID (500 mg total) by mouth for the first 4 weeks before blood and stool samples are collected. Then, participants will take 500 mg of genistein BID (1000 mg total) for the next 4 weeks before collecting fasting blood and stool samples. Afterward, participants will take 750 mg of genistein BID (1500 mg total) for 4 weeks before collecting fasting blood and stool samples. Afterward, participants will have a washout for 6 weeks before returning for fasting blood and stool sample collection.
Study NCT05551819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MDF then RUTF/RUSF
Description: Children randomized to feeding order 1: children will be provided MDF for the first two weeks then crossover to consume RUTF/RUSF for a second two weeks.
Study NCT05551819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF/RUSF then MDF
Description: Children randomized to feeding order 2: children will be provided RUTF/RUSF for the first two weeks then crossover to consume MDF for a second two weeks.
Study NCT04987697 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: counseling
Description: nine 90-minute weekly psychoeducational group sessions facilitated by a licensed mental health counselor (LMHC).
Study NCT05496660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NHE+KT
Description: the Nodic hamstring exercise plus the kinesio taping with tension during 4-week consisting 12 sessions
Study NCT05935293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: iv administration dexmedetomidine
Study NCT05935293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: iv administration dexmedetomidine
Study NCT05808972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride 0.9% (SC)
Description: This trial looks specifically at the type of hydratation liquid. The patients included will receive SC. The volume, frequency of fluid administration and other severe DKA therapies, such as insulin therapy and electrolytes, are prescribed similarly. The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
Study NCT05953363 — intervention group
Intervention type: DEVICE
Intervention: BD NRFit™ Spinal Needles, BD NRFit™ Spinal Introducer Needles, and BD NRFit™ Syringes
Description: Insertion of a BD NRFit™ spinal needle and optional BD NRFit™ Spinal Introducer Needle using a BD NRFit™ Syringe to perform the neuraxial procedure.
Study NCT04900467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer
Description: BNT162b2 (Comirnaty®), Pfizer/BioNTech, mARN vaccine,
Study NCT05496660 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: NHE
Description: the Nodic hamstring exercise plus the kinesio taping without tension during 4-week consisting 12 sessions
Study NCT06182761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib combination with Anlotinib
Description: Sunvozertinib 300 mg once daily (QD) with Anlotinib 12mg once daily （QD in Day 1-14） ，21 days in one cycle.
Study NCT05808972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate (RL)
Description: The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
Study NCT05723874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809
Study NCT05723874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: bosentan
Study NCT04900467 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pfizer
Description: BNT162b2 (Comirnaty®), Pfizer/BioNTech, mARN vaccine,
Study NCT04900467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Moderna
Description: mRNA-1273, COVID-19 Vaccine Moderna, mARN vaccine, administrated by intramuscular
Study NCT04900467 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderna
Description: mRNA-1273, COVID-19 Vaccine Moderna, mARN vaccine, administrated by intramuscular
Study NCT04824274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: Fentanyl 10 mcg will be injected intrathecally during spinal anesthesia.
Study NCT04824274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: Morphine 75 mcg will be injected intrathecally during spinal anesthesia.
Study NCT04824274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Description: Ultrasound-guided bilateral transversus abdominis plane block will be done. 0.375% ropivacaine 15 ml per side will be injected.
Study NCT04824274 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham block
Description: Ultrasound-guided bilateral transversus abdominis plane sham block will be done. Normal saline 15 ml per side will be injected.
Study NCT05629845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic ultrasound-guided therapy
Description: EUS-guided glue injection will be used for secondary prevention of EV or GV rebleeding.
Study NCT04791514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Palmitil
Description: Administered by oral inhalation using a Plastiape capsule-based dry powder inhaler
Study NCT06172621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Associative Plasticity (SCAP)
Description: Paired non-invasive brain and spinal cord stimulation.
Study NCT06172621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Associative Plasticity (SCAP)
Description: Paired non-invasive brain and spinal cord stimulation.
Study NCT06172621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper extremity task-oriented exercise
Description: Participants will perform a range of exercises composed of tasks resembling daily home/community activities such as stacking and sorting small objects, manipulating writing utensils, keys, buttons, etc.
Study NCT06219278 — intervention group
Intervention type: DEVICE
Intervention: Profound Matrix
Description: The source study consisted of up to three treatment visits with treatment intervals 6 weeks ± 2 weeks
Study NCT06498869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hcl 50Mg/Ml Inj
Description: This group will be administered ketamine (0.25-0.50 mg/kg)
Study NCT05895955 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TetraFluvac TF vaccine
Description: The vaccine is a seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like virus and A/Darwin/9/2021 (H3N2)-like virus and B/Austria/1359417/2021 (B/Victoria Lineage)-like virus and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus\] produced by The Government Pharmaceutical Organization (GPO), Thailand.~Each prefilled dose of TetraFluvac TF contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection.
Study NCT05895955 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip vaccine
Description: Vaxigrip vaccine is commercially available seasonal quadrivalent inactivated split virion influenza vaccine \[A/Sydney/5/2021(H1N1) pdm09-like strain and A/Darwin/9/2021 (H3N2)-like strain and B/Austria/1359417/2021-like strain and B/Phuket/3073/2013-like strain, manufactured by Sanofi Pasteur, Ltd. France.~Each prefilled dose of Vaxigrip vaccine contains a total of 60 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection.
Study NCT04884997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: toripalimab
Description: toripalimab 3mg/kg, Q2w;
Study NCT04884997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripalimab
Description: toripalimab 3mg/kg, Q2w;
Study NCT04884997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Injection
Description: Temozolomide 150mg/m2,d1-5,Q4w
Study NCT06109129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXOPULSE Mollii Suit
Description: EXOPULSE Mollii Suit is a personal assistive medical device which is used for low energy whole body transcutaneous electrical stimulation - 20 Volt and 20 Hz. It is composed of a control unit, a jacket and pants with 58 embedded electrodes in direct contact with the skin. EXOPULSE Mollii Suit is used for activation of muscles or relaxation of spastic muscles mediated by a physiological reflex mechanism referred to as reciprocal inhibition. By sending an electrical signal to an antagonistic muscle, the spastic muscle may subsequently relax.
Study NCT05439304 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05630690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL with smart diagnostic handpiece
Description: treatment with IPL following diagnostic with SMART system
Study NCT06292403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: training time will be 30 minutes therapy, once a day, 3 days a week for 8 weeks. were allowed to rest for 3-5 min during each training.
Study NCT06292403 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: training time will be 30 minutes therapy, once a day, 3 days a week for 8 weeks. were allowed to rest for 3-5 min during each training.
Study NCT06292403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: Participants in the (trial group) mirror and strength training group observed the reflection of the exercising arm and leg in the mirror. Participants in the (control group) strength training only group will exercise without a mirror entirely.
Study NCT05645705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
Study NCT05645705 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
Study NCT05645705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LISTERINE Cool Mint Antiseptic Mouthwash
Description: Participants will use 20 mL of LISTERINE Cool Mint Antiseptic Mouthwash for 30 seconds after brushing twice daily.
Study NCT06507982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EWL
Description: the working length determination with EAL method
Study NCT06507982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SWL
Description: In this method, an endodontic motor with a built-in EAL that provides continuous feedback during root canal instrumentation and allows clinicians to make real-time adjustments to the WL. Thus, it provides continuous feedback, allowing the clinician to make real-time adjustments. The motor of devices using this method has automatic apical reverse and automatic apical stop operation. In this way, when the tip of the file reaches the apical foramen, the file safely reverses and stops rotating.
Study NCT06507982 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: RWL
Description: Radiographic method was used for determining the working length
Study NCT05777876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcranial deep brain stimulation
Description: A new non-invasive transcranial deep brain stimulation, Temporal Interference Stimulation (TIS), can focus the stimulation region specifically on the deep brain region without affecting the upper level of the target region. At present, the safety of this method has been preliminarily verified in animals and healthy people, but the brain target of TRD treatment is not clear.
Study NCT05777876 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Electrodes will be placed in the same location on the head as that for the TI intervention; 30 seconds of electrical current will be delivered to the brain (compared to 30 minutes in the experimental intervention arm), therefore it is expected to elicit no changes in neural activity.
Study NCT05777876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation
Description: Receive stimulation in the motor cortex stimulation instead of deep brain.
Study NCT04713644 — intervention group
Intervention type: DRUG
Intervention: Standardized Propofol Administration
Description: Intravenous bolus propofol administration of 0.5 mg/Kg dose, plus 0.5 mg/Kg extra if necessary
Study NCT05385926 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients who had complete response or partial response after at least 3 cycles (no more than 6 cycles) of chemotherapy combined with immunotherapy receive local radiotherapy 21 days. For those non-CR oligo-metastatic disease or symptomatic lesion, SBRT or conventional RT delivered. Maintenance therapy of immunotherapy for 2 years.
Study NCT05632913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
Study NCT04741087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMT-101 (oral)-Dose A
Description: AMT-101 is an orally administered biologic therapeutic, taken once daily.
Study NCT04741087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMT-101 (oral)-Dose B
Description: AMT-101 is an orally administered biologic therapeutic, taken once daily.
Study NCT05566327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: De-implementation Bundle
Description: A multicomponent intervention directed at the drivers of low value preoperative testing.~An administrative change will be implemented whereby medically necessary preoperative tests for patients undergoing scheduled surgery will be ordered at the discretion of a consulting anaesthesiologist only. Workshops will be delivered to surgical, internal medicine, and anaesthesia divisions. The workshop program will include rationale for the policy, discussion of perceived local barriers to implementation and mitigation strategies.The clinical departments will commit to supporting the change in policy. Nurses will be coached to feel comfortable calling the anesthesiologist about any preoperative tests ordered, and the PAC nurses will have the authority to cancel tests. Check boxes will be removed from surgeons' and family physicians' order forms to reduce to ease of ordering the tests.
Study NCT05629845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional endoscopic therapy
Description: conventional endoscopic therapy (VBL for EV or glue injection for GV) for secondary prevention of EV or GV rebleeding.
Study NCT06221137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional circumferential supracrestal fiberotomy
Description: The amount of tooth that need to be extruded will be measured Bonding brackets slot 0,022x0.028 Roth prescription on piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~• Fiberotomy After 2 days of bonding, local anaesthetic solution will be administrated. The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~supracrustal fibrotomy will be performed using 15 c blade (Carvalho, Bauer et al. 2006)
Study NCT06221137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser circumferential supracrestal fiberotomy
Description: * The amount of tooth that need to be extruded will be measured~* Bonding brackets slot 0,022x0.028 Roth prescription~* piggyback for the tooth with (0.016. x 0.022 ) stainless steel main arch wire and 0.0014 nickel titanium auxiliary.~  • Fiberotomy~* After 2 days of bonding, local anaesthetic solution will be administrated.~* The depth of the fibrotomy should be equal to the amount of tooth that need to be extruded.~* A diode laser of 980 nm wavelength will be used The laser tip will be inserted, and incision will be extended around tooth circumference with the system configured to a continuous wave with the movement of the laser tip in an up and down stroking movement The laser tip will be moved in a circumferential manner taking care that all the fibers are lysed.
Study NCT05110404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The high-volume HIIT
Description: patients will undergo a warm up at 65%-70% of HRpeak for 5 minutes, and then they will walk on a treadmill for 4 intervals of 4 min each at an intensity corresponding to 85%-90% of HRpeak with 3 min active recovery interval interval in between at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted. The speed and the inclination of the treadmill will be adjusted between intervals to ensure that all patients are exercising at the desired target heart rate monitored by Pulse Oximeter.
Study NCT05110404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The low-volume HIIT
Description: Each session will start with a 5-minute warm up at 65-70% of peak HR. Then they will walk on a treadmill for 4 intervals of 2 min each at an intensity corresponding to 85%-90% of HRpeak with three intervals of active recovery in between for 2 min at 65%-75% of HRpeak. Finally, a 3-min cool-down period will be permitted.
Study NCT05777876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive transcranial deep brain stimulation with closed-loop
Description: Non-invasive transcranial deep brain stimulation devices based on closed-loop regulation of EEG can improve the accuracy of treatment.
Study NCT05645705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Advanced Gum Alcohol
Description: Participants will use 20 mL of Listerine Advanced Gum Alcohol Rinse for 30 seconds after brushing twice daily.
Study NCT05645705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listerine Advanced Gum Zero
Description: Participants will use 20 mL of Listerine Advanced Gum Zero Rinse for 30 seconds after brushing twice daily.
Study NCT05645705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint
Description: Participants will use 20 mL of LISTERINE ULTRACLEAN Tartar Control Antiseptic Mouthwash Cool Mint Rinse for 30 seconds after brushing twice daily.
Study NCT06550973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique
Description: Rescue techniques, such as pre-cut biliary sphincterotomy/fistulotomy, double guide wire (DGW) technique, wire-guided cannulation over a pancreatic stent and transpancreatic biliary sphincterotomy, will be used at the discretion of the endoscopist \[12\]. After deep cannulation, a cholangiogram to better define the characteristics of the stenosis will be done. The stent will then be inserted over a guidewire and deployed across the stenosis. All stents will be fully covered SEMSs or partially covered SEMSs of 10 mm diameter. The length of the stent will be chosen at the discretion of the endoscopist performing the procedure. A prophylactic pancreatic stent will be placed in patients who will be thought to be at high risk of post-procedure pancreatitis at the discretion of the treating endoscopist.
Study NCT06382480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet with specific macronutrient composition.
Description: The intervention is about an isocaloric diet that differs in terms of distribution of carbohydrates and protein throughout the day. The interventions include a HP-breakfast and a HC-dinner vs. a HC-breakfast and a HP-dinner. A HP low-carb meal (breakfast or dinner) will contain 35%E protein, 35%E carbs, and 30%E fat, and a HC meal (breakfast or dinner) will contain 10%E protein, 60%E carbs, and 30%E fat.